– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve...

Revenue growth expected to accelerate in 2026 Management to host conference call today at 5 p.m. ET to review results and discuss outlook PROVIDENCE, R.I., March 30, 2026 (GLOBE NEWSWIRE) — via IBN — Beeline Holdings, Inc. (Nasdaq: BLNE), the emerging digital mortgage lender and fractional equity platform, today announces financial results for the fourth quarter ended December 31, 2025.  Q4 2025 Financial Highlights Net revenue of $2.5 million, up 127% year-over-year and 8.3% sequentially  Q4 2025 origination volume of $84.7 million, up 44% year-over-yearOperating expenses increased, primarily reflecting $4.2 million in non-cash stock-based compensation; excluding this, operating expenses increased 19% on 127% revenue growth 1Launched BeelineEquity platform and closed initial transactions recorded on the Blockchain...

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration Strengthened leadership team with addition of new Chief Medical Officer and senior appointments bolstering cardiac expertise Cash, cash equivalents...

SAN JOSE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — zSpace, Inc. (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leading provider of augmented and virtual reality (AR/VR) solutions for education, is announcing its financial results for the three and twelve months ended December 31, 2025. “Our fourth quarter results reflect continued progress against our strategic priorities and our focus on controlling what we can control,” said Paul Kellenberger, CEO of zSpace. “In the quarter, software and services comprised 53% of revenue, a 10ppts increase from a year ago, contributing to gross margin expansion of over 840 basis points. This performance was driven by strong customer renewals, deeper adoption of our software offerings and meaningful customer wins across K-12, CTE and workforce pathways. We expanded our platform capabilities with...

MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the first quarter ended March 31, 2026 via news release on Monday, April 27, 2026 after market close. The company will host a webcast with Alain Bédard, Chairman, President and Chief Executive Officer, and David Saperstein, Chief Financial Officer, on Monday, April 27, 2026 at 5:00 PM Eastern Time, to discuss results. Webcast Details:Date: Monday, April 27, 2026 Time: 5:00 PM Eastern Time Live webcast & replay: Presentations & Reports within the Investors section of the Company website. Alternatively for the live webcast visit webcast.ABOUT TFI INTERNATIONAL TFI International Inc. is a North American...

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate...

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 approval is in progress Transitioned to a clinical-stage neurology company with six clinical sites activated in Phase 1/2 STAND study in chronic neuropathic pain Announced in April, third neurology capsid license agreement, this time with Eli Lilly, to deliver genomic medicines for up to five central nervous system disease targets Raised over $130 million in funding since start of 2025 through non-dilutive...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $238.3 Million as of December 31, 2025, and Anticipated Runway into Second Half 2027 BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies...

CAMARILLO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Qualstar Corporation (OTC: QBAK), a trusted provider of scalable data storage and high-efficiency power solutions, today reported financial results for the quarter ended December 31, 2025. 2025 and Recent HighlightsWe achieved 9% year-over-year revenue growth in our Data Storage business. We recently launched the Q1000+ Powered by Orion, an enterprise tape library storage solution designed to be Simply Reliable™, offering superior performance and scalability for short-term backup, disaster recovery, and long-term archiving requirements. We hold over $2.8 million in cash, cash equivalents, and marketable securities, with no outstanding debt.Management Commentary “Despite a nearly $1.9 million decline in our Power Supply business and a slower fourth quarter overall,...

Financial Press Release : Annual results 2025   Reims, March 30, 2026 The Board of Directors of Maison Pommery & Associés met on March 30, 2026, under the chairmanship of Mr. Paul François Vranken, and in the presence of the Statutory Auditors, to approve the Group’s financial statements for the 2025 fiscal year.Consolidated data 31/12/2025*(M€) 31/12/2024(M€) Change(M€) Change(%)Turnover 293.2 304.0 -10.8 -3.6%Current Operating Income 20.0 35.7 -15.7 -44.1%Operating Income 64.1 35.1 +29.0 +82.5%Financial Result -32.6 -33.5 -0.9  Net Income 31.9 0.8 +31.0 +3751.9%Attributable to equity holders of the parent 32.0 0.9 +31.1 +3393.9%*The process of auditing and issuing the audit report for the certification of the consolidated accounts is underway. Business activity: market share gains in a contracting market Maison...